Loading stock data…
$19.56+0.23 (+1.19%)
Braveheart Bio, Inc.
| Metric (USD) | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — |
| Operating Income | -$15.88M↓ | -$15.05M↓ | -$27,000↓ | -$5,000 |
| Net Income | -$14.99M↓ | -$14.28M↓ | -$381,000↓ | -$99,000 |
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small...